MedPath

Clemastine

Generic Name
Clemastine
Brand Names
Wal-hist 12 Hr Relief
Drug Type
Small Molecule
Chemical Formula
C21H26ClNO
CAS Number
15686-51-8
Unique Ingredient Identifier
95QN29S1ID
Background

An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

Indication

For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.

Associated Conditions
Allergic Rhinitis (AR), Angioedema, Common Cold, Urticaria
Clinical Trials
Related News

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Phase 2
Not yet recruiting
Conditions
Depression
Interventions
Drug: Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-03-04
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
80
Registration Number
NCT06591091

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

Phase 2
Not yet recruiting
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2024-03-18
Last Posted Date
2024-03-20
Lead Sponsor
LMU Klinikum
Target Recruit Count
90
Registration Number
NCT06315972

Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome

Phase 3
Recruiting
Conditions
Neurodevelopmental Delay
Williams Syndrome
Child
Interventions
Dietary Supplement: fructose
First Posted Date
2024-03-18
Last Posted Date
2024-03-18
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
50
Registration Number
NCT06315699
Locations
🇨🇳

Qilu Hospital of Shandong University, Tainan, Shangdong, China

Clemastine Treatment in Individuals With Williams Syndrome

Phase 3
Recruiting
Conditions
Williams Syndrome
Interventions
First Posted Date
2023-10-18
Last Posted Date
2024-05-07
Lead Sponsor
Sheba Medical Center
Target Recruit Count
30
Registration Number
NCT06087757
Locations
🇮🇱

Child and Adolescent Psychiatry Unit, Sheba Medical Center, Ramat-Gan, Israel

🇮🇱

Tel Aviv University, Tel Aviv, Israel

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Phase 1
Not yet recruiting
Conditions
Demyelinating Diseases
Demyelination; Corpus Callosum
Multiple Sclerosis Brain Lesion
Multiple Sclerosis Acute and Progressive
Clinically Isolated Syndrome, CNS Demyelinating
Interventions
Drug: Placebo
First Posted Date
2023-10-04
Last Posted Date
2024-07-03
Lead Sponsor
University of California, San Francisco
Target Recruit Count
44
Registration Number
NCT06065670
Locations
🇺🇸

Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco, California, United States

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

Completed
Conditions
Solid Tumor
Interventions
First Posted Date
2023-09-15
Last Posted Date
2024-02-20
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
395
Registration Number
NCT06039137
Locations
🇳🇱

Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Phase 1
Recruiting
Conditions
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis Relapse
Multiple Sclerosis (MS)
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis Benign
Multiple Sclerosis Brain Lesion
Interventions
Drug: Placebo
First Posted Date
2022-05-04
Last Posted Date
2024-07-01
Lead Sponsor
University of California, San Francisco
Target Recruit Count
74
Registration Number
NCT05359653
Locations
🇺🇸

Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco, California, United States

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

Phase 3
Recruiting
Conditions
Multiple Sclerosis
Internuclear Ophthalmoplegia
Interventions
Drug: Placebo
First Posted Date
2022-04-21
Last Posted Date
2024-11-15
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
80
Registration Number
NCT05338450
Locations
🇳🇱

Amsterdam UMC, location VUmc, Amsterdam, Netherlands

Clemastine in Cardiovascular Surgery

Not Applicable
Completed
Conditions
Efficacy and Safety
Interventions
Drug: Saline Solution
First Posted Date
2019-02-01
Last Posted Date
2020-01-13
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
100
Registration Number
NCT03826004
Locations
🇨🇳

Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC, Beijing, Beijing, China

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Phase 1
Recruiting
Conditions
Multiple Sclerosis
Interventions
First Posted Date
2017-04-12
Last Posted Date
2025-04-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
250
Registration Number
NCT03109288
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy